Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PH 80

Drug Profile

PH 80

Alternative Names: ORG 39479; PH-80; PH-80-M; PH80-PMD NS

Latest Information Update: 15 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Pherin Pharmaceuticals
  • Developer Pherin Pharmaceuticals; VistaGen Therapeutics
  • Class Antidepressants; Antimigraines; Steroids
  • Mechanism of Action Neurotransmitter receptor modulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Hot flashes; Migraine; Premenstrual dysphoric disorder

Most Recent Events

  • 09 Jul 2024 PH 80 has patent protection in the European Union, Hong Kong and Japan for the treatment of Migraine prior to July 2024
  • 09 Jul 2024 VistaGen Therapeutics receives a notice of allowance from the IP Australia and Mexican Institute of Industrial Property for PH 80 nasal spray for the treatment of migraine
  • 09 Nov 2023 Vistagen plans a phase IIb trial for Hot flashes in USA (Intranasal, Spray) in the first half of 2025
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top